mhurhangee/patent-ind-claim-en huggingface dataset:
A rechargeable battery pack comprising: a battery cell for being charged and discharged; an electrode terminal provided in a cap plate of the battery cell; a protection member disposed above and spaced apart from the cap plate and electrically protecting the battery cell, comprising a first portion electrically connected to the electrode terminal, and a second portion extending from the first portion; and a protective circuit module disposed above and spaced apart from the protection member and electrically connected to the second portion of the protection member, wherein the second portion of the protection member is connected to a connection portion of the protective circuit module, wherein the protection member further includes a protection element that is connected between the first and second portions in a first direction; and further comprising an insulating tape disposed at an inner side of the protective circuit module in a second direction that crosses the first direction while covering the protection element and the first welding portion, and further comprising a top case that is disposed between the cap plate and the protection member in the second direction while being formed as an insulator, and wherein the top case forms an opened portion that corresponds to at least the electrode terminal and the protection element, and the protection element is placed in the opened portion while being spaced apart from an inner side thereof. a battery cell for being charged and discharged; an electrode terminal provided in a cap plate of the battery cell; a protection member disposed above and spaced apart from the cap plate and electrically protecting the battery cell, comprising a first portion electrically connected to the electrode terminal, and a second portion extending from the first portion; and a protective circuit module disposed above and spaced apart from the protection member and electrically connected to the second portion of the protection member, wherein the second portion of the protection member is connected to a connection portion of the protective circuit module, wherein the protection member further includes a protection element that is connected between the first and second portions in a first direction; and further comprising an insulating tape disposed at an inner side of the protective circuit module in a second direction that crosses the first direction while covering the protection element and the first welding portion, and further comprising a top case that is disposed between the cap plate and the protection member in the second direction while being formed as an insulator, and wherein the top case forms an opened portion that corresponds to at least the electrode terminal and the protection element, and the protection element is placed in the opened portion while being spaced apart from an inner side thereof.
A composition for use in the treatment or prevention of a bacterial infection in a subject, the composition comprising; i) a first material being hydroxyapatite, ii) a second material being calcium sulphate, iii) two or more pharmaceutical compounds, wherein the at least two pharmaceutical compounds are selected from a combination of vancomycin and rifampicin, or a combination of gentamicin and rifampicin, to thereby prevent or reduce or eliminate the occurrence of bacterial resistance against said the pharmaceutical compounds. i) a first material being hydroxyapatite, ii) a second material being calcium sulphate, iii) two or more pharmaceutical compounds, wherein the at least two pharmaceutical compounds are selected from a combination of vancomycin and rifampicin, or a combination of gentamicin and rifampicin,
Compound of formula (I): wherein: R 1 , R 2 each independently represents a hydrogen atom, a C 1 -C 6 -alkyl group, or (CH 2 )OR 5 or (CH 3 )CHNR 6 R 7 , or R 1 and R 2 form together a heterocycle having 5 or 6 ring members, said heterocycle being optionally substituted by one or more C 1 -C 6 -alkyl, =OH, -C(=O)CH 3 groups; R3 represents a hydrogen atom or an OH, C 1 -C 6 -alkyl or =O group; R 4 represents a hydrogen atom, an OH group or a NR 8 R 9 group; ---- represents a single bond or a double bond; R 5 represents a hydrogen atom, a (C 1 -C 6 )alkyl group, or a (C 1 -C 6 )alkylcarbonyl group; R 6 , R 7 , R 8 , R 9 each independently represents a hydrogen atom, a C 1 -C 6 -alkyl group, or a (C 1 -C 6 )alkylcarbonyl group; or a tautomeric, enantiomeric, diastereoisomeric or epimeric form thereof or a pharmaceutically acceptable salt thereof, for use in the treatment and/or prevention of obesity and/or of inflammation associated with obesity and/or with cellulite by increasing Sirt1 activity. R 1 , R 2 each independently represents a hydrogen atom, a C 1 -C 6 -alkyl group, or (CH 2 )OR 5 or (CH 3 )CHNR 6 R 7 , or R 1 and R 2 form together a heterocycle having 5 or 6 ring members, said heterocycle being optionally substituted by one or more C 1 -C 6 -alkyl, =OH, -C(=O)CH 3 groups; R3 represents a hydrogen atom or an OH, C 1 -C 6 -alkyl or =O group; R 4 represents a hydrogen atom, an OH group or a NR 8 R 9 group; ---- represents a single bond or a double bond; R 5 represents a hydrogen atom, a (C 1 -C 6 )alkyl group, or a (C 1 -C 6 )alkylcarbonyl group; R 6 , R 7 , R 8 , R 9 each independently represents a hydrogen atom, a C 1 -C 6 -alkyl group, or a (C 1 -C 6 )alkylcarbonyl group; or a tautomeric, enantiomeric, diastereoisomeric or epimeric form thereof or a pharmaceutically acceptable salt thereof, for use in the treatment and/or prevention of obesity and/or of inflammation associated with obesity and/or with cellulite by increasing Sirt1 activity.
A computer-implemented method for determining articulation parameters, the method comprising: receiving images of a patient's face, wherein the images are taken using a camera system having a depth sensor ; determining fixed points and moving points in the patient's face based on the received images, calculating the articulator parameters based on the determined fixed and moving points, wherein the articulator parameters are chosen from the group consisting of (i) Sides of a Bonwill triangle, (ii) Balkwill angle and (iii) Sagittal condylar path inclination. receiving images of a patient's face, wherein the images are taken using a camera system having a depth sensor ; determining fixed points and moving points in the patient's face based on the received images, calculating the articulator parameters based on the determined fixed and moving points, wherein the articulator parameters are chosen from the group consisting of (i) Sides of a Bonwill triangle, (ii) Balkwill angle and (iii) Sagittal condylar path inclination.
A modular frame system for vacuum pumps, comprising a base frame for a first vacuum pump ; and a separate additional frame , which is provided in addition to the base frame , for a second vacuum pump , wherein the base frame is configured both for a pump operation of the first vacuum pump without the additional frame and without the second vacuum pump and for a joint pump operation of the two vacuum pumps in which the two vacuum pumps form a pumping station and are connected to one another in a technical vacuum manner, and wherein the base frame and the additional frame are configured such that, in order to form the pumping station, the additional frame can be supported at the base frame and the second vacuum pump can be supported at the additional frame , characterized in that a functional module associated with the first vacuum pump , in particular a switch cabinet, and a functional module associated with the second vacuum pump , in particular a switch cabinet, are fastened to the additional frame in different vertical positions, in particular vertically above one another, and are each connectable to the associated vacuum pump , in particular by one or more electrical lines and/or plugin connections. comprising a base frame for a first vacuum pump ; and a separate additional frame , which is provided in addition to the base frame , for a second vacuum pump , wherein the base frame is configured both for a pump operation of the first vacuum pump without the additional frame and without the second vacuum pump and for a joint pump operation of the two vacuum pumps in which the two vacuum pumps form a pumping station and are connected to one another in a technical vacuum manner, and wherein the base frame and the additional frame are configured such that, in order to form the pumping station, the additional frame can be supported at the base frame and the second vacuum pump can be supported at the additional frame , characterized in that a functional module associated with the first vacuum pump , in particular a switch cabinet, and a functional module associated with the second vacuum pump , in particular a switch cabinet, are fastened to the additional frame in different vertical positions, in particular vertically above one another, and are each connectable to the associated vacuum pump , in particular by one or more electrical lines and/or plugin connections.
A float adapter for an electrical connector, comprising: a conductive shell having opposite first and second ends; at least one insulator received in said conductive shell , said at least one insulator having an engagement end and an interface end opposite said engagement end, said interface end having a lead-in tip portion extending outside of one of said first and second ends of said shell, said at least one insulator having an inner bore for receiving an inner contact ; an inner contact being received in said inner bore ; characterized in that a retaining sleeve is disposed around said conductive shell , said retaining sleeve having an engagement member for engaging said at least one insulator through a slot in the shell . a conductive shell having opposite first and second ends; at least one insulator received in said conductive shell , said at least one insulator having an engagement end and an interface end opposite said engagement end, said interface end having a lead-in tip portion extending outside of one of said first and second ends of said shell, said at least one insulator having an inner bore for receiving an inner contact ; an inner contact being received in said inner bore ; characterized in that a retaining sleeve is disposed around said conductive shell , said retaining sleeve having an engagement member for engaging said at least one insulator through a slot in the shell .
Method of increasing the fungicidal activity of an aqueous suspoemulsion composition comprising a triazole and a strobilurin, characterised in that the composition comprises the components: (a) a dispersed oil phase comprising: (i) a solvent having at least one triazole active compound dissolved therein, wherein the triazole active compound is one or more member selected from the group consisting of azaconazole, bitertanol, bromuconazole, cyproconazole, diclobutrazole, difenoconazole, diniconazole, epoxiconazole, etaconazole, fenbuconazole, fluquinconazole, flusilazole, flutriafol, haxaconazole, imibenconazole, ipconazole, metconazole, myclobutanil, paclobutrazol, penconazole, propiconazole, prothioconazole, simeconazole, tebuconazole, tetraconazole, triadimefon, triadimenol, and triticonazole; and (b) a continuous water phase comprising: (i) water having at least one strobilurin active compound suspended therein, wherein the strobilurin active compound is one or more member selected from the group consisting of azoxystrobin, dimoxystrobin, famoxadone, fenamidone, fluoxastrobin, kresoxim-methyl, metominostrobin, picoxystrobin, pyraclostrobin and trifloxystrobin; the method comprising including in the composition at least one alkyl carboxylic acid amide. (a) a dispersed oil phase comprising: (i) a solvent having at least one triazole active compound dissolved therein, wherein the triazole active compound is one or more member selected from the group consisting of azaconazole, bitertanol, bromuconazole, cyproconazole, diclobutrazole, difenoconazole, diniconazole, epoxiconazole, etaconazole, fenbuconazole, fluquinconazole, flusilazole, flutriafol, haxaconazole, imibenconazole, ipconazole, metconazole, myclobutanil, paclobutrazol, penconazole, propiconazole, prothioconazole, simeconazole, tebuconazole, tetraconazole, triadimefon, triadimenol, and triticonazole; and (i) a solvent having at least one triazole active compound dissolved therein, wherein the triazole active compound is one or more member selected from the group consisting of azaconazole, bitertanol, bromuconazole, cyproconazole, diclobutrazole, difenoconazole, diniconazole, epoxiconazole, etaconazole, fenbuconazole, fluquinconazole, flusilazole, flutriafol, haxaconazole, imibenconazole, ipconazole, metconazole, myclobutanil, paclobutrazol, penconazole, propiconazole, prothioconazole, simeconazole, tebuconazole, tetraconazole, triadimefon, triadimenol, and triticonazole; and (b) a continuous water phase comprising: (i) water having at least one strobilurin active compound suspended therein, wherein the strobilurin active compound is one or more member selected from the group consisting of azoxystrobin, dimoxystrobin, famoxadone, fenamidone, fluoxastrobin, kresoxim-methyl, metominostrobin, picoxystrobin, pyraclostrobin and trifloxystrobin; (i) water having at least one strobilurin active compound suspended therein, wherein the strobilurin active compound is one or more member selected from the group consisting of azoxystrobin, dimoxystrobin, famoxadone, fenamidone, fluoxastrobin, kresoxim-methyl, metominostrobin, picoxystrobin, pyraclostrobin and trifloxystrobin;
A radio receiver arranged to operate as a wake-up radio receiver for a main receiver interacting with the radio receiver , the radio receiver comprising a local oscillator arrangement and a controller , wherein the local oscillator arrangement is arranged to provide a signal for down-conversion of radio frequency signal to an intermediate frequency or a baseband frequency in the radio receiver , and the local oscillator arrangement is capable of selectably providing multiple frequency generation qualities, and the controller is arranged to estimate a tolerable frequency generation quality for the current operation of the radio receiver or determine whether the current operation of the radio receiver is satisfactory in sense of a currently provided frequency generation quality, and based on the estimation or determination adjust frequency generation quality of the local oscillator arrangement by selecting one of the multiple frequency generation qualities, wherein the estimation of the tolerable frequency generation quality includes reception of an indication from the main receiver with information about an interfering signal in an adjacent radio channel. the local oscillator arrangement is arranged to provide a signal for down-conversion of radio frequency signal to an intermediate frequency or a baseband frequency in the radio receiver , and the local oscillator arrangement is capable of selectably providing multiple frequency generation qualities, and the controller is arranged to estimate a tolerable frequency generation quality for the current operation of the radio receiver or determine whether the current operation of the radio receiver is satisfactory in sense of a currently provided frequency generation quality, and based on the estimation or determination adjust frequency generation quality of the local oscillator arrangement by selecting one of the multiple frequency generation qualities, wherein the estimation of the tolerable frequency generation quality includes reception of an indication from the main receiver with information about an interfering signal in an adjacent radio channel.
A compound of the formula (I) wherein L 1 represents -CO-, alkandiyl, -alkyl-CO- or -CO-alkyl-; L 2 represents -CO-, alkandiyl, -alkyl-CO- or -CO-alkyl-; L 3 represents -CO-, alkandiyl, -alkyl-CO- or -CO-alkyl-; R 1 represents hydrogen, acyl, carbamoyl, alkylaminocarbonyl, dialkylaminocarbonyl, arylcarbonyl, cycloalkylcarbonyl or heterocyclylcarbonyl; R 2 represents optionally substituted alkyl, aralkyl or heteroaralkyl; R 3 represents hydrogen, or represents optionally substituted alkyl, aralkyl or heteroaralkyl; R 4 represents optionally substituted alkandiyl, alkendiyl, alkyndiyl, cycloalkyldiyl, alkylcycloalkyldiyl, alkylcycloalkylalkyldiyl, aryldiyl, alkylaryldiyl, alkylarylalkyldiyl; R 5 represents hydrogen, or represents optionally substituted alkyl, aralkyl or heteroaralkyl; R 6 represents hydrogen, or represents optionally substituted alkyl, aralkyl or heteroaralkyl; provided that at least two of the substituents R 2 , R 3 , R 5 and R 6 are aralkyl or heteroaralkyl; wherein at least one of R 2 or R 3 is a biphenyl-Ci-alkyl optionally substituted with tert-butyl; n is 0, 1, 2, 3 or 4; and m is 0 or 1; Q is -NH 2 , -NH-C(NH)-NH 2 or -NH-C(N-alkyl)-NH-alkyl; X is NH, O or S; Z 1 is -CH 2 -; Z 2 is a direct bond, alkandiyl, cycloalkyldiyl or aryldiyl; or a salt and solvate of such compound. L 1 represents -CO-, alkandiyl, -alkyl-CO- or -CO-alkyl-; L 2 represents -CO-, alkandiyl, -alkyl-CO- or -CO-alkyl-; L 3 represents -CO-, alkandiyl, -alkyl-CO- or -CO-alkyl-; R 1 represents hydrogen, acyl, carbamoyl, alkylaminocarbonyl, dialkylaminocarbonyl, arylcarbonyl, cycloalkylcarbonyl or heterocyclylcarbonyl; R 2 represents optionally substituted alkyl, aralkyl or heteroaralkyl; R 3 represents hydrogen, or represents optionally substituted alkyl, aralkyl or heteroaralkyl; R 4 represents optionally substituted alkandiyl, alkendiyl, alkyndiyl, cycloalkyldiyl, alkylcycloalkyldiyl, alkylcycloalkylalkyldiyl, aryldiyl, alkylaryldiyl, alkylarylalkyldiyl; R 5 represents hydrogen, or represents optionally substituted alkyl, aralkyl or heteroaralkyl; R 6 represents hydrogen, or represents optionally substituted alkyl, aralkyl or heteroaralkyl; provided that at least two of the substituents R 2 , R 3 , R 5 and R 6 are aralkyl or heteroaralkyl; wherein at least one of R 2 or R 3 is a biphenyl-Ci-alkyl optionally substituted with tert-butyl; n is 0, 1, 2, 3 or 4; and m is 0 or 1; Q is -NH 2 , -NH-C(NH)-NH 2 or -NH-C(N-alkyl)-NH-alkyl; X is NH, O or S; Z 1 is -CH 2 -; Z 2 is a direct bond, alkandiyl, cycloalkyldiyl or aryldiyl; or a salt and solvate of such compound.
An electrical bus bar comprising: a first mounting portion adapted to be connected to a first counter connector, a second mounting portion adapted to be connected to a second counter connector and a flexible section between the first and second mounting portions , wherein the bus bar comprises at least a flat first part and at least a flat second part , wherein each flat part extends from the first mounting portion to the second mounting portion and is arranged in a stacked configuration, wherein the flat first part and the flat second part is made of a metal sheet , wherein a first stripe of the metal sheet extends from a body edge of the flat first part to a body edge of the flat second part forming a first link , wherein the first link is dimensioned to keep a first contact surface of the flat first part and a second contact surface of the flat second part in intimate contact, characterized in that the flat first part comprises an arm , protruding from the first contact surface , located in the flexible section and wherein the flat second part comprises an opening located in the flexible section , wherein the arm is formed to protrude into the opening, thereby limiting movement of the flat first part in relation to the flat second part .
A process comprising (A) providing a mixture comprising (a) a first population of microscopic structures with the appearance of particles comprising a recombinase, a single-strand DNA binding protein (SSB), and a first oligonucleotide comprising a first detectable label; and (b) a second population of microscopic structures with the appearance of particles comprising a recombinase, a single-strand DNA binding protein (SSB) and a second oligonucleotide comprising a second detectable label, wherein: the first and second oligonucleotides are different, the first and second detectable labels are different, and the first and second population of microscopic structures with the appearance of particles can be independently detected in the mixture, wherein the mixture comprises a crowding agent and either: i. UvsX and UvsY; or ii. UvsX and gp32; and (B) detecting microscopic structures with the appearance of particles in the mixture. (A) providing a mixture comprising (a) a first population of microscopic structures with the appearance of particles comprising a recombinase, a single-strand DNA binding protein (SSB), and a first oligonucleotide comprising a first detectable label; and (b) a second population of microscopic structures with the appearance of particles comprising a recombinase, a single-strand DNA binding protein (SSB) and a second oligonucleotide comprising a second detectable label, wherein: the first and second oligonucleotides are different, the first and second detectable labels are different, and the first and second population of microscopic structures with the appearance of particles can be independently detected in the mixture, wherein the mixture comprises a crowding agent and either: i. UvsX and UvsY; or ii. UvsX and gp32; (a) a first population of microscopic structures with the appearance of particles comprising a recombinase, a single-strand DNA binding protein (SSB), and a first oligonucleotide comprising a first detectable label; and (b) a second population of microscopic structures with the appearance of particles comprising a recombinase, a single-strand DNA binding protein (SSB) and a second oligonucleotide comprising a second detectable label, wherein: the first and second oligonucleotides are different, the first and second detectable labels are different, and the first and second population of microscopic structures with the appearance of particles can be independently detected in the mixture, wherein the mixture comprises a crowding agent and either: i. UvsX and UvsY; or ii. UvsX and gp32; the first and second oligonucleotides are different, the first and second detectable labels are different, and the first and second population of microscopic structures with the appearance of particles can be independently detected in the mixture, wherein the mixture comprises a crowding agent and either: i. UvsX and UvsY; or ii. UvsX and gp32; i. UvsX and UvsY; or ii. UvsX and gp32; and (B) detecting microscopic structures with the appearance of particles in the mixture.
A composition for use in preventing scar formation during wound healing, characterized in that the composition comprises adenine and/or a pharmaceutically acceptable salt thereof as a sole active ingredient effective on preventing scar formation during wound healing, wherein the adenine and/or the pharmaceutically acceptable salt thereof is administrated to a mammal in need of such treatment.